The Gryphon Group was established in 2019 by its partners, Wayne Childs and Brian Goldie after 25 years of working within the industry. The team at The Gryphon Group has been supporting the Pharmaceutical and Biotechnology industry as a boutique consultancy and outsource resource for companies who are well-established or entering the Canadian market. With their extensive corporate and consulting experience, The Gryphon Group keeps up to date with the evolving changes within the industry and aligns its insights to ensure it supports the new realities.
The Gryphon Group has established themselves as key strategists in Oncology, Specialty and Rare Diseases. The Gryphon Group supports and assists corporate teams in managing the portfolio & lifecycle of their brands with strategies and tactics that align brand goals and sales objectives. This includes being launch specialists and understanding what resources need to be deployed to be successful. They specialize in supporting companies through their network of contacts within Cancer Agencies, Hospitals and GPO's. They facilitate both in person and virtual ad-boards that provide critical feedback to commercial needs. They also support the dissemination of clinical information to community treaters through academic KOL’s. They have become a trusted advisor in the areas of Brand Performance, Resource Deployment and Sales Effectiveness.